Press Releases

Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities

Download PDF

Los Angeles, CA, April 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the addition of eight new hospitals Endonovo’s SofPulse® medical device is approved for use. The eight hospitals are located in the following geographic areas: 7 Hospitals in Nevada and 1 Hospital in North Carolina.

Endonovo's SofPulse® is an FDA-Cleared non-invasive therapeutic medical device for reduction of postoperative pain and edema. SofPulse® represents a low-cost, drug-free solution proven in studies to reduce the use of opioids following surgical procedures, which can help prevent opioid dependency. The SofPulse® PEMF (Pulsed Electromagnetic Frequency) therapy is non-invasive and non-pharmacologic with no known side effects and no potential for overdose or dependency. SofPulse® has been proven in clinical studies and in current hospital use to reduce pain and edema postoperatively while improving recovery in patients using the SofPulse® device. Additionally, SofPulse® has been studied extensively in soft tissue post-operative pain management. Learn more at

Endonovo CEO Alan Collier states, “Our Endonovo sales and marketing team continues to expand distribution by working with hospital administrators and medical professionals daily. Adding eight additional hospitals to our distribution network demonstrates SofPulse® marketing efforts are consistently striving to bring this innovative postoperative pain and edema reduction device to the public. Making the SofPulse® device available to every patient having a surgical procedure is our nationwide marketing goal to help resolve the opioid crisis gripping America. With the incredible health benefits SofPulse® provides we are excited about the progress and the strong positive market feedback we have been receiving regarding the demand and need for SofPulse® in hospitals nationwide.”

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki

Primary Logo

Source: Endonovo Therapeutics, Inc.